The Alliance for Regenerative Medicine (ARM) is the preeminent international organization focused specifically on the issues facing regenerative medicine and advanced therapies. We are advocates for progress in gene therapy, cell therapy, and tissue engineering.
Working with our members and policymakers, we foster investment, research & development, and successful commercialization of safe, effective, and transformational therapies for patients around the world.
2020 Priorities:
2020 Priorities:
2020 Priorities:
ARM is the leading voice in the regenerative medicine sector educating stakeholders on policy issues affecting the development of and patient access to regenerative medicines. For a full list of ARM’s presentations and publications, click here.
Produced by the Marwood Institute and funded by ARM, this report uses a “Transformative Therapy Value Model,” and demonstrates that durable cell or gene therapies for multiple myeloma, sickle cell disease, and hemophilia A could provide cumulative cost-savings of $33B over the next ten years.
New cell and gene therapies are changing the face of medicine – and raising questions on how to pay for durable and potentially curative new treatments. Watch this webinar playback to gain insights from experts in the developer, payor, and policy spheres.
ARM CEO Janet Lambert presented at ASGCT’s 2020 Virtual Conference on value demonstration for cell & gene therapy. The presentation cites findings from ARM’s library of original policy analyses.
